Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma

This study has been withdrawn prior to enrollment.
Information provided by:
Mayo Clinic Identifier:
First received: October 12, 2009
Last updated: April 18, 2016
Last verified: February 2011

Rationale: Giving bortezomib and low doses of chemotherapy and total-body irradiation before a donor stem cell transplant or peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving sirolimus and tacrolimus before and after transplant may stop this from happening.

Purpose: This phase I/II trial is studying the side effects and best dose of bortezomib before donor stem cell transplant in treating patients with multiple myeloma.

Condition Intervention Phase
Multiple Myeloma
Refractory Multiple Myeloma
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Procedure: allogeneic bone marrow transplantation
Drug: bortezomib
Drug: melphalan
Drug: anti-thymocyte globulin
Drug: sirolimus
Drug: tacrolimus
Radiation: total-body irradiation
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Study of a Novel Reduced Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation in Patients With Multiple Myeloma

Resource links provided by NLM:

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Tolerability as assessed by CTCAE v3.0 (Phase I)
  • Assessment of toxicity (Phase I)
  • Proportion of successes
  • Transplant-related mortality (TRM) (Phase II) [ Time Frame: 100 days ]
  • Rate acute graft-vs-host disease (GVHD) (Phase I)

Secondary Outcome Measures:
  • Rate of grades II-IV and grades III-IV acute graft-vs-host disease (GVHD)
  • Cumulative rate of chronic GVHD
  • Overall response
  • Overall survival
  • Progression-free survival

Enrollment: 0
Arms Assigned Interventions
Experimental: Arm 1
CONDITIONING: Patients receive bortezomib IV and then undergo fractionated total-body irradiation on days -5 and -2. Patients receive thymoglobulin IV over 6 hours on days -5 to -2 and melphalan IV over 30 minutes on days -4 to -3. ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -3, patients receive oral sirolimus and taper beginning on day 61. Beginning on day -2, patients receive oral or IV tacrolimus and taper beginning on day 101.
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Undergo transplantation
Procedure: allogeneic bone marrow transplantation
Undergo transplantation
Other Names:
  • bone marrow therapy, allogeneic
  • bone marrow therapy, allogenic
  • transplantation, allogeneic bone marrow
  • transplantation, allogenic bone marrow
Drug: bortezomib
Given IV
Other Names:
  • LDP 341
  • MLN341
  • PS-341
Drug: melphalan
Given IV
Other Names:
  • Alkeran
  • CB-3025
  • L-PAM
  • L-phenylalanine mustard
  • L-Sarcolysin
  • Melfalan
Drug: anti-thymocyte globulin
Given IV
Other Names:
  • ATG
  • lymphocyte immune globulin
  • Thymoglobulin
Drug: sirolimus
Given orally
Other Names:
  • AY 22989
  • RAPA
  • Rapamune
  • rapamycin
  • SILA 9268A
  • SLM
Drug: tacrolimus
Given oral or IV
Other Names:
  • Advagraf
  • FK 506
  • Prograf
  • Protopic
Radiation: total-body irradiation
Undergo total-body irradiation
Other Name: TBI

Detailed Description:


I. To determine the maximum tolerated dose (MTD) of bortezomib when used in a novel conditioning regimen for patients undergoing allogeneic stem cell transplantation for multiple myeloma.

II. To evaluate the tolerability and feasibility of this novel conditioning regimen and GVHD prophylaxis strategy incorporating several anti-myeloma agents, including bortezomib, in patients undergoing allogeneic stem cell transplantation for multiple myeloma.

III. To obtain an initial assessment of the efficacy of this novel conditioning regimen.

Outline: This is a phase I dose-escalation study of bortezomib followed by a phase II study.

Reduced-Intensity Conditioning: Patients receive bortezomib IV and then undergo fractionated total-body irradiation on days -5 and -2. Patients receive thymoglobulin IV over 6 hours on days -5 to -2 and melphalan IV over 30 minutes on days -4 to -3.

Allogenic Stem Cell Transplantation: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0.

Graft versus Host Disease Prophylaxis: Beginning on day -3, patients receive oral sirolimus and taper beginning on day 61. Beginning on day -2, patients receive oral or IV tacrolimus and taper beginning on day 101. After completion of the study treatment, patients are followed every 3 months.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ECOG performance status (PS) 0, 1, or 2
  • Diagnosis of symptomatic multiple myeloma
  • High risk myeloma as defined by progressive disease =< 12 months after high dose chemotherapy and autologous HSC transplant or presences of poor prognostic features such as deletion of chromosome 13 or hypodiploidy by standard cytogenetics, or t(4; 14) by fluorescence in situ hybridization (FISH), or t(14;16) by FISH, or 17p- by FISH, or plasma cell labeling index >= 3%
  • Availability of a HLA fully-matched or 1 mismatch related donor by low-resolution HLA typing for the loci A, B, C, DRB1 and DQB1 or HLA fully-matched unrelated donor by high-resolution typing for loci A, B, C and DRB1 and at least low-resolution for loci DQB1
  • Recovery from toxicity of previous chemotherapy (excludes grade 1 neurotoxicity and hematological toxicity)
  • Physically and psychologically capable of undergoing bone marrow or PBSC transplant
  • Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
  • Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control for the during of the study
  • Male subject agrees to use an acceptable method for contraception for the duration of the study

Exclusion Criteria:

  • Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV hear failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
  • NOTE: Prior to study entry, and ECG abnormality at screening has to be documented by the investigator as not medically relevant
  • Significant cardiac dysfunction defined as left ventricle ejection fraction < 40% or presence of symptomatic coronary artery disease
  • Significant pulmonary disease defined as FEV < 50% or CLCO < 50% of the predicted values
  • Pre existing peripheral neuropathy grade > 1
  • Significant renal dysfunction defined as estimated creatinine clearance < 50 ml/min
  • Significant liver dysfunction defined as total bilirubin >= 2 x upper limit of normal (ULN) or AST, ALT >= 3 x ULN
  • Seroreactive for HIV, HTLV I or II, HBV, HCV
  • Presence of uncontrolled bacterial, viral, or fungal infection
  • Known allergy to any of the component of the investigational treatment regimen or required ancillary treatments
  • Considered unable to tolerate the included doses of total body irradiation due to previous treatment with radiation
  • Female subject is pregnant or breast-feeding
  • Other active concurrent malignancy
  • Prior allogeneic bone marrow/peripheral blood stem cell transplant
  • Received other investigational drugs =< 14 days prior to enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00995059

Sponsors and Collaborators
Mayo Clinic
Study Chair: Martha Q. Lacy, M.D. Mayo Clinic
Principal Investigator: James L. Slack, M.D. Mayo Clinic
  More Information

Responsible Party: Martha Q. Lacy, M.D., Mayo Clinic Cancer Center Identifier: NCT00995059     History of Changes
Other Study ID Numbers: MC078F
NCI-2009-01249 ( Registry Identifier: NCI-CTRP )
08-003029 ( Other Identifier: Mayo Clinic IRB )
MC078F ( Other Identifier: Mayo Clinic Cancer Center )
Study First Received: October 12, 2009
Last Updated: April 18, 2016

Keywords provided by Mayo Clinic:
stage I multiple myeloma
stage II multiple myeloma
stage III multiple myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Antilymphocyte Serum
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Myeloablative Agonists processed this record on May 22, 2017